Life Science Cluster Flemingsberg
About
Life Science Cluster Flemingsberg is a project that works to strengthen collaboration between industry, academia, and healthcare and foster enhanced conditions for establishment, growth, and innovation within life science in Flemingsberg.
Through this initiative, we work to help stakeholders find the right infrastructure, expertise and connections, create meeting places and networks that connect the ecosystem, and promote sustainable collaboration and circular economy.
Life Science Cluster Flemingsberg is led by the Flemingsberg Science Foundation and co-financed by the European Regional Development Fund. The project is carried out in collaboration with co-financiers Region Stockholm, Botkyrka Municipality, Huddinge Municipality, and Hemsö, and in close partnership with Karolinska Institutet and Region Stockholm’s Life Science Office.
What can we do for you?
We’re here to help you establish, find lab space or specialized research infrastructure, connect with the right partners, or simply explore all the opportunities available in Flemingsberg. Get in touch with us and we’ll tell you more about how we can help you or your company navigate the ecosystem.
CONTACT OUR TEAM
Natasha Bank
Cluster Manager, Flemingsberg Science
natasha.bank@flemingsbergscience.se
+46 737 77 14 77
Angela Hoyer
Networks and Event Manager, Flemingsberg Science
angela.hoyer@flemingsbergscience.se
+46 767 71 63 03
Ellen Mäkipiha
Communications Officer, Flemingsberg Science
ellen.makipiha@flemingsbergscience.se
+46 761 17 76 37
EVENTS
NEWS
A national resource for tomorrow’s treatments – Karolinska ATMP Center is now inaugurated
With a clear message of hope for the future and a powerful spirit of collaboration, the Karolinska ATMP Center in Flemingsberg was inaugurated at the end of August. The center is a collaboration between Karolinska Institutet and Karolinska University Hospital and will serve as a national resource for the production of advanced therapies (ATMPs), where research, clinical trials, and treatments work seamlessly together to deliver groundbreaking therapies to patients.
Meetings That Shape the Future: Flemingsberg Science at Almedalen
In June this year, the foundation took part in the annual Almedalen Week, the world’s largest democratic meeting place for everyone who wants to join the discussions on current societal issues. This year, we had a special focus on Life Science, an area and cluster that has long been a natural part of Flemingsberg, and which is now growing stronger than ever.
Meet us at NLSDays
In the south of Stockholm you’ll find Flemingsberg, home to a vibrant life science cluster that’s rapidly emerging as an attractive location for life science companies. Here, academia, business and society form a dynamic ecosystem, fueling innovation and growth. And with more companies establishing and collaborations further deepening, the opportunity to expand and invest have never been greater. This year, we are therefore participating in NLSDays in Gothenburg, where we will showcase Flemingsberg's unique strengths and invite more stakeholders to become part of our thriving life science environment.
Novum – More Than a Place
The Park and the real estate company Hemsö have entered into a collaboration which means Novum Research Park in Flemingsberg will offer a first-class coworking environment for researchers, innovators, and creative minds who want to become part of a growing Life Science cluster. At the same time, the Flemingsberg Science Foundation is launching a film about Novum—playful and with a touch of drama.
The Life Science business of Merck KGaA, Darmstadt, Germany Becomes a Trusted Partner of the Flemingsberg Science Foundation
The Life Science business of Merck KGaA, Darmstadt, Germany, and Flemingsberg Science Foundation collaborate to promote Life Science sector in Flemingsberg. This strategic partnership aims to strengthen development of ATMP (Advanced Therapy Medicinal Products).
AlzeCure Pharma – a hope in the fight against Alzheimer’s
Neurological diseases and the pain area are struggling with great medical needs, including the lack of broad-spectrum drugs. Those are gaps in the market that AlzeCure Pharma wants to fill, and they are well on their way. They recently received a grant from the European Innovation Council (EIC) to finance a clinical phase 2 study of the drug candidate NeuroRestore ACD856 for Alzheimer’s disease.
